Compounded GLP-1 safety: what the FDA shortage list change means

When semaglutide left FDA shortage list in 2024, compounded versions became legally restricted. Pricing, access, and clinical implications.

1 min readReviewed May 2026

By Sarah Editor, MA Journalism, Certified Menopause Coach · Medically reviewed by Jane Smith, MD, MD, NAMS-certified · menopause nams

LicensedCA +2 moreVerify credentials →

Last medically reviewed: 5/15/2026 · Last updated: 5/15/2026 · Next review due: May 2027

Disclosure: Jane Smith, MD declares no financial relationship with the telehealth providers featured in this content.

Affiliate link Advertiser Disclosure: This site is reader-supported. We may earn an affiliate commission when you sign up for a service through links on our site. This does not influence our editorial recommendations or medical reviews. Read our full disclosure.

When semaglutide left FDA shortage list in 2024, compounded versions became legally restricted. Pricing, access, and clinical implications.

How we work — three pages, three answers